Nader Hanna

Dr. Nader Hanna


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2025 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
SPSourav K Podder
Sourav K Podder
ADAllison Doermann
Allison Doermann
GIGeorge Ibrahim
George Ibrahim
MBMatthew Bs Bowen
Matthew Bs Bowen
SKScott H Koeneman
Scott H Koeneman
Nader HannaNader Hanna
Nader Hanna
BACKGROUND: The American College of Surgeons (ACS) NSQIP Colectomy-Targeted database provides valuable metrics on surgical outcomes by using clinical data to enhance quality improvement efforts. However, the quality measures offered in the ACS NSQIP semiannual report do not stratify for the indication of colectomy. We aim to compare postoperative outcomes in patients undergoing colectomy for colon cancer, infectious causes, and inflammatory bowel disease (IBD). STUDY DESIGN: A retrospective review of patients undergoing colectomy was performed using the ACS NSQIP Colectomy-Targeted database from 2012 to 2022. Logistic regression models were used to compare the 30-day postoperative outcomes of patients who underwent colectomy for colon cancer, infectious causes, and IBD while adjusting for preoperative risk factors. RESULTS: There were 158,560 patients who underwent colectomy for colon cancer, 90,827 patients for infectious causes, and 30,548 patients for IBD. In unadjusted analysis, patients undergoing colectomy for infectious causes had the highest rates of mortality (2.6%) and morbidity (27.6%). After adjusting for covariates, patients with IBD undergoing colectomy had significantly higher odds of morbidity compared to those undergoing colectomy for colon cancer (odds ratio 1.3, 95% CI [1.1 to 1.4]) and infectious causes (odds ratio 1.3 [1.2 to 1.4]). Patients with IBD had significantly higher odds of experiencing venous thromboembolism, surgical site infections, prolonged ileus, and readmission within 30 days compared to both colon cancer and infectious causes patients. CONCLUSIONS: This study demonstrates that the indication for colectomy impacts postoperative outcomes. Reporting risk-adjusted outcomes based on the underlying disease etiology could lead to identifying high-risk patients, improving benchmarking outcomes, and developing targeted quality initiatives.

26 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BDBasel Darawsha
Basel Darawsha
LHLavu Harish
Lavu Harish
CYCharles Yeo
Charles Yeo
Nader HannaNader Hanna
Nader Hanna
ANAvinoam Nevler
Avinoam Nevler
Background: Pancreatic cancer is an aggressive malignancy, largely due to its vague clinical presentation and delayed diagnosis. Knowledge of the risk factors is essential to combat this disease. Increasing interest has been directed toward immune-related disorders and their effect on pancreatic cancer development. Studies have investigated the relationship between asthma and pancreatic cancer; however, findings are inconsistent, with some studies reporting a protective association, while others failed to detect any differences. In light of these inconsistent findings, we conducted a systematic review of the available literature to clarify the link between asthma and pancreatic cancer. Methods: We identified studies published from 1978 through December 2025 that investigated the association between asthma and pancreatic cancer using PubMed, Scopus, and Embase databases, searched on 2 February 2026. Eligible studies were English-language comparative studies evaluating the association between asthma and pancreatic cancer, including case–control and cohort studies. Eligible outcomes were pancreatic cancer incidence or pancreatic cancer mortality. Studies that did not assess both asthma and pancreatic cancer were excluded. Studies were classified by design, assessed for bias and quality using the Newcastle–Ottawa Scale, and presented as a narrative review. This review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline. Results: A total of 27 studies were included, comprising 14 case–control studies and 13 cohort studies. Overall, the available literature demonstrates discordant findings regarding the association between asthma and pancreatic cancer. While some studies suggest a potential inverse relationship, others report a null or even positive association. Conclusions: The current evidence on the association between asthma and pancreatic cancer remains inconsistent. The discrepancies across studies likely reflect variations in study design, differences in asthma ascertainment, and inconsistent adjustment for established confounders. Future studies with objective asthma diagnosis and adequate confounder control are warranted to clarify this association.

12 February 2026 in Surgical Clinics of North America
Verified
Journal Article
Closed access
DHDavid N. Hanna
David N. Hanna
AHAndrew N. Hanna
Andrew N. Hanna
Nader HannaNader Hanna
Nader Hanna

1 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
LCLawrence Chiang
Lawrence Chiang
ABAdam Seth Bodzin
Adam Seth Bodzin
DLDaniel Lin
Daniel Lin
Nader HannaNader Hanna
Nader Hanna
SKScott Koeneman
Scott Koeneman
RZRichard Zheng
Richard Zheng
Background: Effects of neoadjuvant immunotherapy (NIT) before liver resection are not well-described in hepatocellular carcinoma (HCC). Survival and R0 resection rates in HCC patients undergoing curative-intent resection with or without NIT were evaluated. Methods: A retrospective study of stage I-III HCC patients undergoing hepatectomy from the 2017–2022 National Cancer Database was performed. Patients receiving NIT were exactly matched 1:3 to non-NIT patients by clinical stage. Primary outcomes were margin positivity, 30- and 90-day mortality, and overall survival. Results: After matching 510 patients, 97 received NIT and 291 did not (non-NIT). Resections included segmental (178, 45.9%), lobar (149, 38.4%), and extended hepatectomy (61, 15.7%). The NIT group included ablation (6, 6.2%), radiation (25, 25.8%), and Y90 (18, 18.6%). The non-NIT group included 124 (42.6%) chemotherapy, 23 (7.9%) chemotherapy plus ablation, 31 (10.7%) chemotherapy plus radiation, four (1.4%) radiation, and 109 (37.5%) upfront surgery. NIT patients were treated more at high-volume (41.2% vs. 0%) and academic/research centers (85.4% vs. 50.5%). NIT R0 resection rates were higher (97.9% vs. 93.2%, p = 0.009). Median survival was higher in the NIT group (59.1 vs. 50.4 months, p = 0.002); 30- and 90-day mortality were similar. NIT was not independently associated with improved survival in multivariable Cox regression (HR 0.73, 95% CI [0.35, 1.55]), although the effect estimate indicates a protective effect may be present. Conclusions: NIT was associated with higher R0 resection rates and overall survival without increasing short-term mortality in selected patients at high-volume academic centers, but was not independently associated with survival when adjusting for confounders. As we continue to see increasing use of immunotherapy in the neoadjuvant setting, these findings should be considered hypothesis-generating and warrant prospective validation before widespread adoption for HCC.